Result of AGM

RNS Number : 3881Y
e-Therapeutics plc
02 September 2009
 




Press Release

02 September 2009


 

e-Therapeutics plc

('e-Therapeutics' or 'the Company')

Result of Annual General Meeting


 

e-Therapeutics plc (AIM: ETX), the systems biology drug discovery company, today announces that all resolutions proposed at the Company's Annual General Meeting held today were duly passed.


Ends -



For more information:




e-Therapeutics plc

www.etherapeutics.co.uk 

Malcolm Young

malcolm@etherapeutics.co.uk 

+44 (0) 191 233 1317



Nominated Advisor & Broker:

Canaccord Adams Ltd

www.canaccordadams.com 

Robert Finlay

Robert.Finlay@CanaccordAdams.com 

+44 (0) 20 7050 6500



Media enquiries:

Abchurch Communications

www.abchurch-group.com

Heather Salmond Stephanie Cuthbert / Simone Alves 

simone.alves@abchurch-group.com 

+44 (0) 20 7398 7700




Notes to Editors


e-Therapeutics plc is a systems biology drug discovery company. It has developed proprietary computational systems to swiftly and accurately analyse and predict how medicines interact with cells in the body. This optimises the probability of identifying drug candidates with desirable efficacy and low toxicity. The Company applies its novel, systematic approach to three areas of activity: 

discovery of new drugs;

discovering novel uses for existing drugs; and

analysis of the interactions between different drugs. 


Amongst e-Therapeutics' pipeline of compounds in development are novel antibiotics that have been shown to kill the 'superbug' MRSA, and a novel cancer chemotherapy that has been shown to kill malignant cells at safe doses in a very short time. Other candidate therapies in development are targeted at atherosclerosis, asthma and depression. The Company is currently in negotiation with a number of pharmaceutical companies, and is progressing the preclinical and clinical development of these products. 


For further information on e-Therapeutics visit www.etherapeutics.co.uk



This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGUUVWRKBRKRRR
UK 100

Latest directors dealings